Disabled homolog 2 is required for migration and invasion of prostate cancer cells

Abstract

Disabled homolog 2 (DAB2) is frequently deleted or epigenetically silenced in many human cancer cells. Therefore, DAB2 has always been regarded as a tumor suppressor gene. However, the role of DAB2 in tumor progression and metastasis remains unclear. In this study, DAB2 expression was upregulated along with human prostate cancer (PCa) progression. DAB2 overexpression or knockdown effects in LNCaP and PC3 cell lines were verified to address the biological functions of DAB2 in PCa progression and metastasis. LNCaP and PC3 cell lines were generated from human PCa cells with low and high metastatic potentials, respectively. The results showed that DAB2 shRNA knockdown can inhibit the migratory and invasive abilities of PC3 cells, as well as the tumorigenicity, whereas DAB2 overexpression enhanced LNCaP cell migration and invasion. Further investigation showed that DAB2 regulated the cell migration associated genes in PC3 cells, and the differential DAB2 expression between LNCaP and PC3 cells was partly regulated by histone 4 acetylation. Therefore, DAB2 may play an important role in PCa progression and metastasis.

Keywords

DAB2 / prostate cancer / migration / invasion / acetylation

References

[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin2011; 61(2): 69–90

[2] Jilg CA, Ketscher A, Metzger E, Hummel B, Willmann D, Rüsseler V, Drendel V, Imhof A, Jung M, Franz H, Hölz S, Krönig M, Müller JM, Schüle R. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget2014; 5(24): 12646–12664

[3] Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem2005; 280(43): 36529–36540

[4] Xie S, Xie Y, Zhang Y, Huang Q. Effects of miR-145 on the migration and invasion of prostate cancer PC3 cells by targeting DAB2. Hereditas (Beijing) (Yi Chuan)2014; 36(1): 50–57 (in Chinese)

[5] Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol1994; 52(2): 247–252

[6] Fu L, Rab A, Tang LP, Rowe SM, Bebok Z, Collawn JF. Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem J2012; 441(2): 633–643

[7] Moore R, Cai KQ, Tao W, Smith ER, Xu XX. Differential requirement for Dab2 in the development of embryonic and extra-embryonic tissues. BMC Dev Biol2013; 13(1): 39

[8] Jiang Y, Luo W, Howe PH. Dab2 stabilizes Axin and attenuates Wnt/β-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions. Oncogene2009; 28(33): 2999–3007

[9] Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol2010; 12(3): 286–293

[10] Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell2009; 139(5): 871–890

[11] Zhang Z, Chen Y, Tang J, Xie X. Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review. Pak J Med Sci2014; 30(2): 432–437

[12] Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998; 16(18): 2381–2387

[13] Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX. Restoration of positioning cintrol following disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000; 19(42): 4847–4854

[14] Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene2012; 31(6): 764–775

[15] Teckchandani A, Toida N, Goodchild J, Henderson C, Watts J, Wollscheid B, Cooper JA. Quantitative proteomics identifies a Dab2/integrin module regulating cell migration. J Cell Biol2009; 186(1): 99–111

[16] Chetrit D, Ziv N, Ehrlich M. Dab2 regulates clathrin assembly and cell spreading. Biochem J2009; 418(3): 701–715

[17] Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S. Morphogenesis of human endothelial cells is inhibited by DAB2 via Src. FEBS Lett2008; 582(17): 2542– 2548

[18] Zhang Y, Xie S, Zhou Y, Xie Y, Liu P, Sun M, Xiao H, Jin Y, Sun X, Chen Z, Huang Q, Chen S. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm. Cell Reports2014; 8(6): 1989–2002

[19] Liu Y, Song N, Ren K, Meng S, Xie Y, Long Q, Chen X, Zhao X. Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development. PLoS ONE2013; 8(11): e78417

[20] Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckhäberle E, Gevensleben H, Rody A. Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res2013; 33(2): 371–377

[21] Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol2011; 38(4): 1093–1101

[22] Fu H, Wen JF, Hu ZL, Luo GQ, Ren HZ. Knockdown of fascin1 expression suppresses the proliferation and metastasis of gastric cancer cells. Pathology2009; 41(7): 655–660

[23] Murray MY, Birkland TP, Howe JD, Rowan AD, Fidock M, Parks WC, Gavrilovic J. Macrophage migration and invasion is regulated by MMP10 expression. PLoS ONE2013; 8(5): e63555

[24] Xie XM, Zhang ZY, Yang LH, Yang DL, Tang N, Zhao HY, Xu HT, Li QC, Wang EH. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol2013; 43(5): 1636–1642

[25] Prunier C, Howe PH. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to mesenchymal transition (EMT). J Biol Chem2005; 280(17): 17540–17548

[26] Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX. Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinonic acid in embryonic carcinoma cells. J Biol Chem2001; 276(50): 47303–47310

[27] Morris SM, Cooper JA. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic2001; 2(2): 111–123

[28] Xu XX, Yi T, Tang B, Lambeth JD. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene1998; 16(12): 1561–1569

[29] Hocevar BA, Prunier C, Howe PH. Disabled-2 (Dab2) mediates transforming growth factor β (TGFβ)-stimulated fibronectin synthesis through TGFβ-activated kinase 1 and activation of the JNK pathway. J Biol Chem2005; 280(27): 25920–25927

[30] Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci2004; 117( 20): 4619–4628

[31] Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule disabled-2 links the transforming growth factor b receptors to the Smad pathway. EMBO J2001; 20(11): 2789–2801

Acknowledgements

We thank Dr. Xiaochun Fei of Ruijin Hospital for providing PCa patient samples. We thank all the laboratory staff for the helpful discussions. This work was supported by the State Education Commission Program for New Century Excellent Talents in University (NCET-09-0541).

Compliance with ethics guidelines

Yinyin Xie, Yuanliang Zhang, Lu Jiang, Mengmeng Zhang, Zhiwei Chen, Dan Liu, and Qiuhua Huang declare no conflicts of interest. All institutional and national guidelines for the care and use of laboratory animals were followed in this study.

Electronic Supplementary Material Supplementary material is available in the online version of this article at http://dx.doi.org/10.1007/s11684-015-0401-3 and is accessible for authorized users.

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg